Donald A. Bergstrom, President of R&D at Relay Therapeutics, Inc. (NASDAQ:RLAY), filed a Form 4 on October 30, 2026, disclosing a sale of 2,252 shares of common stock on October 28, 2026, to cover income tax withholding obligations arising from the vesting of restricted stock units.

Key Highlights

  • Shares sold: 2,252 shares of Relay Therapeutics common stock were disposed of on October 28, 2026, at a price of $18.62 per share.
  • Purpose of sale: According to the filing, the sale was made solely to cover the reporting person's income tax withholding obligations upon the vesting of 5,012 RSU shares on October 27, 2026.
  • No discretion exercised: The filing states the reporting person "had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs."
  • Post-transaction ownership: Following the transaction, Bergstrom beneficially owned 396,878 shares directly, including 5,013 shares underlying RSUs.
  • Role of reporting person: Donald A. Bergstrom is identified in the filing as an officer with the title President, R&D.

RSU Vesting Triggers Mandatory Tax-Withholding Sale for Relay Therapeutics President of R&D

According to the Form 4 filed with the SEC on October 30, 2026, Donald A. Bergstrom, President of R&D at Relay Therapeutics, Inc., disposed of 2,252 shares of the company's common stock on October 28, 2026, at a price of $18.62 per share. The filing identifies the transaction code as "S," indicating a sale in the open market.

The filing explains that the sale was directly connected to the vesting of 5,012 shares of restricted stock units on October 27, 2026. Per the footnotes, the transaction was carried out to satisfy Bergstrom's income tax withholding obligations and was executed in accordance with the issuer's policies on RSU vesting. The filing further notes that the reporting person had no discretion over the sale.

Following the reported transaction, Bergstrom's total direct beneficial ownership stood at 396,878 shares, a figure that the filing notes includes 5,013 shares underlying RSUs. The Form 4 was signed by Soo-Yeun Lim as attorney-in-fact on October 30, 2026, and was filed as a single reporting person disclosure covering non-derivative securities only.

What Was Disclosed

Relay Therapeutics officer Donald A. Bergstrom disclosed a mandatory sale of 2,252 common shares at $18.62 on October 28, 2026, to cover tax withholding on 5,012 vested RSUs, leaving him with 396,878 shares of direct beneficial ownership, including 5,013 shares underlying RSUs.